FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma

Blood

Volumn 118, Issue 14, 2011, Pages 3911-3921

  Elliott, Natalina E ^a   Cleveland, Susan M ^a   Grann, Victor ^b   Janik, John ^c   Waldmann, Thomas A ^d   Davé, Utpal P ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b Mailman School of Public Health   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROCYTE BAND 4.1 PROTEIN; EZRIN; JANUS KINASE 3; JANUS KINASE 3 INHIBITOR; MOESIN; RADIXIN; TOFACITINIB; UNCLASSIFIED DRUG;

ADULT; AMINO TERMINAL SEQUENCE; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; GAIN OF FUNCTION MUTATION; GENETIC SCREENING; HUMAN; HUMAN CELL; INDUCED MUTATION; MISSENSE MUTATION; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; SOMATIC MUTATION; T CELL LEUKEMIA;

EID: 80053638747     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-12-319467     Document Type: Article

References (55)

1. Taylor GP, Matsuoka M. Natural history of adult T-cell leukemia/lymphoma and approaches to therapy. Oncogene. 2005;24(39):6047-6057. (Pubitemid 43086122)
2. Kami M, Hamaki T, Miyakoshi S, et al. Allogeneic haematopoietic stem cell transplantation for the treatment of adult T-cell leukaemia/lymphoma. Br J Haematol. 2003;120(2):304-309. (Pubitemid 36194182)
3. Matsuoka M, Jeang KT. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer. 2007;7(4):270-280. (Pubitemid 46480972)
4. Robek MD, Ratner L. Immortalization of T lymphocytes by human T-cell leukemia virus type 1 is independent of the tax-CBP/p300 interaction. J Virol. 2000;74(24):11988-11992. (Pubitemid 32222352)
5. Peloponese JM Jr, Kinjo T, Jeang KT. Human T-cell leukemia virus type 1 Tax and cellular transformation. Int J Hematol. 2007;86(2):101-106. (Pubitemid 47425185)
6. Jeang KT, Giam CZ, Majone F, Aboud M. Life, death, and tax: role of HTLV-I oncoprotein in genetic instability and cellular transformation. J Biol Chem. 2004;279(31):31991-31994. (Pubitemid 39014642)
7. Takemoto S, Mulloy JC, Cereseto A, et al. Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins. Proc Natl Acad Sci U S A. 1997;94(25):13897-13902. (Pubitemid 28009681)
8. Bohnlein E, Lowenthal JW, Wano Y, Franza BR, Ballard DW, Greene WC. HIV-1, HTLV-I and the interleukin-2 receptor: insights into transcriptional control. Haematol Blood Transfus. 1989;32:393-401.
9. Malek TR. The biology of interleukin-2. Annu Rev Immunol. 2008;26:453-479. (Pubitemid 351600382)
10. Lin JX, Leonard WJ. Signaling from the IL-2 receptor to the nucleus. Cytokine Growth Factor Rev. 1997;8(4):313-332. (Pubitemid 28201656)
11. Nicot C, Mulloy JC, Ferrari MG, et al. HTLV-1 p12(I) protein enhances STAT5 activation and decreases the interleukin-2 requirement for proliferation of primary human peripheral blood mononuclear cells. Blood. 2001;98(3):823-829.
12. Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009;228(1):273-287.
13. Fung M, Chu Y-L, Fink JL, Wallace A, McGuire K. IL-2- and STAT5-regulated cytokine gene expression in cells expressing the Tax protein of HTLV-1. Oncogene. 2005;24(29):4624-4633. (Pubitemid 41032600)
14. Takeda S, Maeda M, Morikawa S, et al. Genetic and epigenetic inactivation of tax gene in adult T-cell leukemia cells. Int J Cancer. 2004;109(4):559-567. (Pubitemid 38339647)
15. Migone TS, Lin JX, Cereseto A, et al. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science. 1995;269(5220):79-81.
16. Xu X, Kang SH, Heidenreich O, Okerholm M, O'Shea JJ, Nerenberg MI. Constitutive activation of different Jak tyrosine kinases in human T cell leukemia virus type 1 (HTLV-1) tax protein or virus-transformed cells. J Clin Invest. 1995;96(3):1548-1555.
17. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-1790. (Pubitemid 40570926)
18. Norton A, Fisher C, Liu H, et al. Analysis of JAK3, JAK2, and C-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of Down syndrome blasts in children with Down syndrome. Blood. 2007;110(3):1077-1079. (Pubitemid 47267455)
19. Walters DK, Mercher T, Gu TL, et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell. 2006;10(1):65-75.
20. Mullighan CG, Zhang J, Harvey RC, et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2009;106(23):9414-9418.
21. Tepass U. FERM proteins in animal morphogenesis. Curr Opin Genet Dev. 2009;19(4):357-367.
22. Chen M, Cheng A, Chen YQ, et al. The amino terminus of JAK3 is necessary and sufficient for binding to the common gamma chain and confers the ability to transmit interleukin 2-mediated signals. Proc Natl Acad Sci U S A. 1997;94(13):6910-6915.
23. Chen M, Cheng A, Candotti F, et al. Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains. Mol Cell Biol. 2000;20(3):947-956. (Pubitemid 30044232)
24. Ghoreschi K, Laurence A, O'Shea JJ. Selectivity and therapeutic inhibition of kinases: to be or not to be? Nat Immunol. 2009;10(4):356-360.
25. West K. CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders. Curr Opin Investig Drugs. 2009;10(5):491-504.
26. Chrencik JE, Patny A, Leung IK, et al. Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6. J Mol Biol. 16;400(3):413-433.
27. Thomis DC, Gurniak CB, Tivol E, Sharpe AH, Berg LJ. Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science. 1995;270(5237):794-797.
28. Schmitt TM, Zuniga-Pflucker JC. Induction of T cell development from hematopoietic progenitor cells by delta-like-1 in vitro. Immunity. 2002;17(6):749-756. (Pubitemid 35477794)
29. Klucher K, Lopez D, Daley G. Secondary mutation maintains the transformed state in BaF3 cells with inducible BCR/ABL expression. Blood. 1998;91(10):3927-3934. (Pubitemid 28225762)
30. Cornejo MG, Kharas MG, Werneck MB, et al. Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models. Blood. 2009;113(12):2746-2754.
31. Grann VR, Ziv E, Joseph CK, et al. Duffy (Fy), DARC, and neutropenia among women from the United States, Europe and the Caribbean. Br J Haematol. 2008;143(2):288-293.
32. Cacalano NA, Migone TS, Bazan F, et al. Autosomal SCID caused by a point mutation in the N-terminus of Jak3: mapping of the Jak3-receptor interaction domain. EMBO J. 1999;18(6):1549-1558. (Pubitemid 29127068)
33. Dunty J, Gabarra-Niecko V, King M, Ceccarelli D, Eck M, Schaller M. FERM domain interaction promotes FAK signaling. Mol Cell Biol. 2004;24(12):5353-5368. (Pubitemid 38738170)
34. Girault JA, Labesse G, Mornon JP, Callebaut I. The N-termini of FAK and JAKs contain divergent band 4.1 domains. Trends Biochem Sci. 1999;24(2):54-57.
35. Zhou YJ, Chen M, Cusack NA, et al. Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases. Mol Cell. 2001;8(5):959-969. (Pubitemid 34031799)
36. O'Shea JJ, Husa M, Li D, et al. Jak3 and the pathogenesis of severe combined immunodeficiency. Mol Immunol. 2004;41(6-7):727-737. (Pubitemid 38824626)
37. Lin JX, Mietz J, Modi WS, John S, Leonard WJ. Cloning of human Stat5B. Reconstitution of interleukin-2-induced Stat5A and Stat5B DNA binding activity in COS-7 cells. J Biol Chem. 1996;271(18):10738-10744. (Pubitemid 26145810)
38. Murray PJ. The JAK-STAT signaling pathway: input and output integration. J Immunol. 2007;178(5):2623-2629. (Pubitemid 46333135)
39. Ungureanu D, Saharinen P, Junttila I, Hilton DJ, Silvennoinen O. Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1. Mol Cell Biol. 2002;22(10):3316-3326. (Pubitemid 34453973)
40. Zhou YJ, Hanson EP, Chen YQ, et al. Distinct tyrosine phosphorylation sites in JAK3 kinase domain positively and negatively regulate its enzymatic activity. Proc Natl Acad Sci U S A. 1997;94(25):13850-13855. (Pubitemid 28009673)
41. Lietha D, Cai X, Ceccarelli DF, Li Y, Schaller MD, Eck MJ. Structural basis for the autoinhibition of focal adhesion kinase. Cell. 2007;129(6):1177-1187. (Pubitemid 46891044)
42. Boggon TJ, Li Y, Manley PW, Eck MJ. Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. Blood. 2005;106(3):996-1002. (Pubitemid 41076445)
43. Roberts JL, Lengi A, Brown SM, et al. Janus kinase 3 (JAK3) deficiency: clinical, immunologic, and molecular analyses of 10 patients and outcomes of stem cell transplantation. Blood. 2004;103(6):2009-2018. (Pubitemid 38326214)
44. Changelian PS, Moshinsky D, Kuhn CF, et al. The specificity of JAK3 kinase inhibitors. Blood. 2008;111(4):2155-2157. (Pubitemid 351451528)
45. Pise-Masison CA, Radonovich M, Dohoney K, et al. Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability. Blood. 2009;113(17):4016-4026.
46. Kirken RA, Rui H, Malabarba MG, et al. Activation of JAK3, but not JAK1, is critical for IL-2-induced proliferation and STAT5 recruitment by a COOH-terminal region of the IL-2 receptor beta-chain. Cytokine. 1995;7(7):689-700.
47. Chen J, Petrus M, Bryant BR, et al. Induction of the IL-9 gene by HTLV-I Tax stimulates the spontaneous proliferation of primary adult T-cell leukemia cells by a paracrine mechanism. Blood. 2008;111(10):5163-5172.
48. Yamanaka K, Clark R, Rich B, et al. Skin-derived interleukin-7 contributes to the proliferation of lymphocytes in cutaneous T-cell lymphoma. Blood. 2006;107(6):2440-2445. (Pubitemid 43345565)
49. Funakoshi-Tago M, Pelletier S, Matsuda T, Parganas E, Ihle JN. Receptor specific downregulation of cytokine signaling by autophosphorylation in the FERM domain of Jak2. EMBO J. 2006;25(20):4763-4772. (Pubitemid 44607022)
50. Kameda T, Shide K, Shimoda HK, et al. Absence of gain-of-function JAK1 and JAK3 mutations in adult T cell leukemia/lymphoma. Int J Hematol. 92(2):320-325.
51. Hidaka T, Nakahata S, Hatakeyama K, et al. Down-regulation of TCF8 is involved in the leukemogenesis of adult T-cell leukemia/lymphoma. Blood. 2008;112(2):383-393.
52. Pancewicz J, Taylor JM, Datta A, et al. Notch signaling contributes to proliferation and tumor formation of human T-cell leukemia virus type 1- associated adult T-cell leukemia. Proc Natl Acad Sci U S A. 2010;107(38):16619- 16624.
53. Ju W, Zhang M, Jiang JK, et al. CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP. Blood. 2011;117(6):1938-1946.
54. Kubota S, Siomi H, Hatanaka M, Pomerantz RJ. Cis/trans-activation of the interleukin-9 receptor gene in an HTLV-I-transformed human lymphocytic cell. Oncogene. 1996;12(7):1441-1447. (Pubitemid 26135160)
55. Malka Y, Hornakova T, Royer Y, et al. Ligandindependent homomeric and heteromeric complexes between interleukin-2 or -9 receptor subunits and the gamma chain. J Biol Chem. 2008;283(48):33569-33577.